AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up
FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo
- AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker’s COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 million plus other costs by the end of 2021. Oxford Biomedica said in a statement that under the deal it would mass-produce the potential vaccine, AZD1222, for the novel coronavirus for a period of 18 months, which may be further extended by another 18 months into 2022 and 2023.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccines'The US_FDA announced that a public meeting of the Vaccines and Related Biological Products Advisory Committee will be held on Oct. 22, 2020, to discuss the general matter of the development, authorization, and/or licensure of [covid19 vaccines].'
Read more »
Companies Rush to Shore Up Covid-19 Testing Ahead of Flu SeasonPublic-health officials and lab executives are trying to avoid a repeat of July, when demand overwhelmed testing capacity and wait times grew.
Read more »
COVID-19 vaccine diplomacy: Mexico courts allies across ideological spectrumMexico is pressing ahead with an effort to forge COVID-19 vaccine alliances across a wide ideological spectrum of countries from France to Cuba as a World Health Organization (WHO) vaccine initiative will fall short of its needs.
Read more »
Trump's favorability and perceptions of COVID-19 response stagnate post-convention: POLLPresident Trump's efforts to build his appeal and define his opponent at the RNC, had little apparent impact on the electorate, a new ABC News/Ipsos finds.
Read more »